

41
12-22-03
1646
Express Mail Label No. 98395256245 12-1903

Customer No.: 07278

Docket No.: 02650/100H399-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 23 2003

In re Application of: Marc E. WEKSLER, et al..

Serial No.: 10/099,880

Art Unit: 1646

TECH CENTER 1600/2900

Filed: March 14, 2002

Examiner: O. Chernyshev

For: **ANTI-AMYLOID PEPTIDE ANTIBODY BASED DIAGNOSIS AND
TREATMENT OF A NEUROLOGICAL DISEASE OR DISORDER**

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated September 22, 2003, please enter the following
in the above-identified application:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on
page 3 of this paper.

Remarks/Arguments begin on page 7 of this paper.

AMENDMENT TO THE SPECIFICATION

On page 31, lines 1-14, please replace paragraphs one and two with the following amended paragraph:

The invention provides a method for assessing risk of a neurodegenerative disease or disorder in a subject. The method comprises comparing a level of anti-amyloid peptide β -amyloid-42 ($A\beta_{42}$) antibody in a biological sample from a subject to a normal level, wherein a lower level in the biological sample from the subject indicates the risk presence of the disease or disorder. In a specific embodiment, the disease or disorder is Alzheimer's Disease (AD); ~~in a further specific embodiment, the amyloid peptide is β -amyloid-42 ($A\beta_{42}$).~~

~~In addition, the discovery that certain neurodegenerative diseases or disorders are associated with a deficiency of anti-amyloid antibodies provides a method of treating such a disease or disorder in a subject. This method comprises administering a therapeutically effective amount of a human anti-amyloid peptide antibody to a subject believed to suffer from the immune deficiency or disorder. For example, the disease or disorder can be Alzheimer's Disease (AD). In such an embodiment, the amyloid peptide can be β -amyloid-42 ($A\beta_{42}$).~~